Author(s):
Vandna Dewangan, Ram Kumar Sahu, Trilochan Satapathy
Email(s):
vandnadewangan543@gmail.com
DOI:
10.52711/2321-5836.2022.00041 
Address:
Vandna Dewangan*, Ram Kumar Sahu, Trilochan Satapathy
Department of Pharmacology, Columbia Institute of Pharmacy, Near Vidhansabha, Village Tekari, Raipur, (C.G.) India – 493111.
*Corresponding Author
Published In:
Volume - 14,
Issue - 4,
Year - 2022
ABSTRACT:
The direct reporting of adverse drug reactions by patients is becoming an increasingly important topic for discussion in the hospital of Pharmacovigilance. Voluntary adverse drug reaction (ADR) reporting is fundamental to medical drug safety surveillance; however, substantial under-reporting exists and is the main limitation of the system. At this time, hospital accepts consumer reports. The World Health Organization estimates that in 2005 and as well as 2019-2021 pneumococcal infections were responsible for the death of 1.6 million human worldwide. Pneumonia, the lungs become filled with fluid and inflamed, leading to breathing difficulties. For some people, breathing problems can become severe enough to require treatment at the hospital with oxygen or even a ventilator. The pneumonia that COVID-19 causes tends to take hold in both lungs. Moxifloxacin, a fluoroquinolone antibiotic, is used for the treatment of respiratory tract, pelvic inflammatory disease, skin, and intra-abdominal infections. Its safety profile is considered favorable in most reviews but has been challenged with respect to rare but potentially fatal toxicities. The most common adverse drug reaction (ADR) constipation is nausea, vomiting, fatigue, alopecia, drowsiness, myelosuppression, skin reactions, anorexia, mucositis, diarrhoea and Medicines that have been particularly implicated in adverse drug reaction-related hospital admissions include anti-platelets, anticoagulants, cytotoxics, immunosuppressant’s, diuretics, anti-diabetics and antibiotics.
Cite this article:
Vandna Dewangan, Ram Kumar Sahu, Trilochan Satapathy. Incidence of Moxifloxacin serious adverse drug reactions in Pneumococcal infections virus infected patients detected by a Pharmacovigilance program by laboratory signals in a Tertiary hospital in Chhattisgarh (India). Research Journal of Pharmacology and Pharmacodynamics.2022;14(4)237-5. doi: 10.52711/2321-5836.2022.00041
Cite(Electronic):
Vandna Dewangan, Ram Kumar Sahu, Trilochan Satapathy. Incidence of Moxifloxacin serious adverse drug reactions in Pneumococcal infections virus infected patients detected by a Pharmacovigilance program by laboratory signals in a Tertiary hospital in Chhattisgarh (India). Research Journal of Pharmacology and Pharmacodynamics.2022;14(4)237-5. doi: 10.52711/2321-5836.2022.00041 Available on: https://rjppd.org/AbstractView.aspx?PID=2022-14-4-7
REFERENCE:
1. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. The Lancet. 2011 Apr 9;377(9773):1264-75.
2. Gereige RS, Laufer PM. Pneumonia. Pediatrics in Review. 2013 Oct;34(10):438-56.
3. Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. The American journal of medicine. 1994 Apr 1;96(4):313-20.
4. Prayle A, Atkinson M, Smyth A. Pneumonia in the developed world. Paediatric respiratory reviews. 2011 Mar 1;12(1):60-9.
5. Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. The Lancet. 1987 Mar 21;329(8534):671-4.
6. Kollef MH. Prevention of ventilator-associated pneumonia. Critical Care Infectious Diseases Textbook. 2001:707-17.
7. Copetti R, Cattarossi L. Ultrasound diagnosis of pneumonia in children. La radiologia medica. 2008 Mar;113(2):190-8.
8. Kollef MH. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Critical care medicine. 2004 Jun 1;32(6):1396-405.
9. Morgan MS. Diagnosis and treatment of Panton–Valentine leukocidin (PVL)-associated staphylococcal pneumonia. International journal of antimicrobial agents. 2007 Oct 1;30(4):289-96.
10. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not?. Critical care. 2020 Dec;24(1):1-3.
11. Verghese AB, Berk SL. Bacterial pneumonia in the elderly. Medicine. 1983 Sep 1;62(5):271-85.
12. Mulholland EK, Simoes EA, Costales MO, McGrath EJ, Manalac EM, Gove S. Standardized diagnosis of pneumonia in developing countries. The Pediatric infectious disease journal. 1992 Feb 1;11(2):77-81.
13. Fujiwara H, Nishimoto N, Hamano Y, Asanuma N, Miki S, Kasayama S, Suemura M. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Modern rheumatology. 2009 Feb;19(1):64-8.
14. Torres A, El-Ebiary M, Riquelme R, Ruiz M, Celis R. Community-acquired pneumonia in the elderly. InSeminars in respiratory infections 1999 Jun 1 (Vol. 14, No. 2, pp. 173-183).
15. Wilkins TR, Wilkins RL. Clinical and radiographic evidence of pneumonia. Radiologic technology. 2005 Nov 1;77(2):106-10.
16. Chen X, Yin YH, Zhang MY, Liu JY, Li R, Qu YQ. Investigating the mechanism of ShuFeng JieDu capsule for the treatment of novel Coronavirus pneumonia (COVID-19) based on network pharmacology. International journal of medical sciences. 2020;17(16):2511.
17. Convertino I, Tuccori M, Ferraro S, Valdiserra G, Cappello E, Focosi D, Blandizzi C. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Critical Care. 2020 Dec;24(1):1-6.
18. Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety. Drugs in R&D. 2012 Jun;12(2):71-100.
19. Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clinical therapeutics. 2004 Jul 1;26(7):940-50.
20. Chen R, Ma W, Yu X, Liu X, Zhu J, Liang H, Wu X, Guo T. Intravenous moxifloxacin in routine hospital treatment of respiratory tract infections in China: results of a multicenter, noninterventional study. International Journal of General Medicine. 2011;4:317.
21. Onoh A, Linnebur SA, Fixen DR. Moxifloxacin-induced tinnitus in an older adult. Therapeutic Advances in Drug Safety. 2018 Apr;9(4):219-21.
22. Abramova AA, Gavrilova SM. Estimation of ADR'S risk in hospitalized patients with community-acquired pneumonia. In Science Health 2020. Клинические и теоретические аспекты современной медицины 2020 (pp. 37-37).
23. Ball P. Adverse drug reactions: implications for the development of fluoroquinolones. Journal of Antimicrobial Chemotherapy. 2003 May 1;51(suppl_1):21-7.
24. Hofer-Dueckelmann C. Multiple drugs Various toxicities leading to death in elderly. Reactions. 2011 Dec 10;1381:10.
25. Bassis AV. Pneumococcal vaccine First report of cutaneous Rosai-Dorfman disease. Reactions. 2011 Nov 12;1377:12.
26. Ferner RE. Adverse drug reactions. Medicine. 2016 Jul 1;44(7):416-21.
27. Härmark L, van Hunsel F, Grundmark B. ADR reporting by the general public: lessons learnt from the Dutch and Swedish systems. Drug safety. 2015 Apr;38(4):337-47.
28. Beijer HJ, De Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharmacy World and Science. 2002 Apr;24(2):46-54.
29. Stipanowich TJ. ADR and the “Vanishing Trial”: the growth and impact of “Alternative Dispute Resolution”. Journal of Empirical Legal Studies. 2004 Nov;1(3):843-912.
30. Roberts S, Palmer M. Dispute processes: ADR and the primary forms of decision-making. Cambridge University Press; 2005 Oct 20.
31. Webber S, Wilkinson AR, Lindsell D, Hope PL, Dobson SR, Isaacs D. Neonatal pneumonia. Archives of disease in childhood. 1990 Feb 1;65(2):207-11.
32. Ding R, Logemann JA. Pneumonia in stroke patients: a retrospective study. Dysphagia. 2000 Mar;15(2):51-7.
33. Stevens RM, Teres D, Skillman JJ, Feingold DS. Pneumonia in an intensive care unit: a 30-month experience. Archives of Internal Medicine. 1974 Jul 1;134(1):106-11.
34. Cook DJ, Kollef MH. Risk factors for ICU-acquired pneumonia. Jama. 1998 May 27;279(20):1605-6.
35. Venkatesan P, Gladman J, Macfarlane JT, Barer D, Berman P, Kinnear W, Finch RG. A hospital study of community acquired pneumonia in the elderly. Thorax. 1990 Apr 1;45(4):254-8.
36. Scott JA, Wonodi C, Moïsi JC, Deloria-Knoll M, DeLuca AN, Karron RA, Bhat N, Murdoch DR, Crawley J, Levine OS, O’Brien KL. The definition of pneumonia, the assessment of severity, and clinical standardization in the Pneumonia Etiology Research for Child Health study. Clinical infectious diseases. 2012 Apr 1;54(suppl_2):S109-16.
37. Lutfiyya MN, Henley E, Chang LF, Reyburn SW. Diagnosis and treatment of community-acquired pneumonia. American family physician. 2006 Feb 1;73(3):442-50.